This paper was presented at the 2023 American Society of Clinical Oncology (ASCO) held in Chicago Illinois by Drs Lili Mao, Lu Si, Jie Dai,et

This paper was presented at the 2023 American Society of Clinical Oncology (ASCO) held in Chicago Illinois by Drs Amr Hesham Abdelhamid Ahmed, Marika D.

This paper was presented at the 2023 American Society of Clinical Oncology (ASCO) held in Chicago Illinois by Drs Catherine Handy Marshall, Benjamin A. Teply,

This paper was presented at the 2023 American Society of Clinical Oncology (ASCO) held in Chicago Illinois by Drs Liuwen Yu, Bangwei Zeng, Minyan Chen

This paper was presented at the 2023 American Society of Clinical Oncology (ASCO) held in Chicago Illinois by Drs Liuwen Yu, Bangwei Zeng, Minyan Chen

This paper was presented at the 2023 American Society of Clinical Oncology (ASCO) held in Chicago Illinois by Drs Sheau Wen Lok, Iris Tung, Angelyn

This paper was presented at the 2023 American Society of Clinical Oncology (ASCO) held in Chicago Illinois by Drs Erika P. Hamilton, Ololade Dosunmu et

This paper was presented at the 2023 American Society of Clinical Oncology (ASCO) held in Chicago Illinois by Drs Ezra Rosen, Manish Sharma et al

This paper was presented at the 2023 American Society of Clinical Oncology (ASCO) held in Chicago Illinois by Drs Yael Bar, Aylin S. Dedeoglu from

• The randomised phase 3 COMMANDS trial compares the efficacy and tolerability of luspatercept versus epoetin alfa in patients with transfusion-dependent, lower-risk myelodysplastic syndromes who